• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine
AbstractThromboembolism is the third leading vascular disease, with a high annual incidence of 1 to 2 cases per 1000 individuals within the general population. The broader term venous thromboembolism generally refers to deep vein thrombosis, pulmonary embolism, and/or a combination of both. Therefore, thromboembolism can affect both – the central and peripheral veins. Arterial thromboembolism causes systemic ischemia by disturbing blood flow and oxygen supply to organs, tissues, and cells causing, therefore, apoptosis and/or necrosis in the affected tissues. Currently applied antithrombotic drugs used, e.g. to protect af...
Source: EPMA Journal - August 15, 2022 Category: International Medicine & Public Health Source Type: research

UCLA raises $611 million in 2020 –21, supporting students and advancing critical research
UCLA raised more than $611 million in gifts and pledges in the fiscal year ending June 30, exceeding its annual goal and drawing donors from all 50 states and 72 countries.“Generous donors at all levels have continued to partner with UCLA to effect meaningful change on campus, in the community and around the world,” said Chancellor Gene Block. “Despite a challenging year, our friends have once again demonstrated their extraordinary commitment to UCLA’s mission of education, research and service.”In response to conditions created by the COVID-19 pandemic, many donors focused on students ’ need to adapt to distan...
Source: UCLA Newsroom: Health Sciences - October 4, 2021 Category: Universities & Medical Training Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news